OVID · Ovid Therapeutics Inc. · Insider Trading

Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date.

Each RSU represents a contingent right to receive one share of Common Stock.

The shares subject to the stock option will vest in 36 equal monthly installments commencing on July 15, 2026, subject to the Reporting Person's continued services through each such date.

Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of 50% of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $22,500. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.

The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date.

Each RSU represents a contingent right to receive one share of Common Stock.

The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes 28,756 shares acquired under the Issuer's employee stock purchase plan.

25% of the shares subject to the Stock Option will vest and become exercisable on January 1, 2027 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.

Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.

Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

The Series A Warrants will terminate upon the earlier of (a) the 30th calendar day following date on which we publicly announce the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of our OV4071 product candidate; provided that such 30-calendar day period shall not commence unless and until a registration statement covering the resale of the shares of Common Stock issuable upon exercise of the Series A Warrants is effective; and (b) October 6, 2030.

The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.

Each Series B Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.

Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.

The Preferred Stock had no expiration date.

The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.

Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.

The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.

The shares subject to the stock option will vest in 36 equal monthly installments commencing on April 3, 2025, subject to the Reporting Person's continued services through each such date.

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Each RSU represents a contingent right to receive one share of Common Stock.

The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date.

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date.

The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date.

The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date.

The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date.

The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date.

The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date.

25% of the shares subject to the Stock Option will vest and become exercisable on September 9, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.

50% of the shares subject to the option shall vest on July 30, 2025, and the remaining shares subject to the option shall vest in 12 equal monthly installments thereafter, subject to Reporting Person's continuous service on each such date.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.76 to $2.78 inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc., any security holder of Ovid Therapeutics Inc., or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4.

25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.

The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date.

25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.

Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date.

Each RSU represents a contingent right to receive one share of Common Stock.